Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

PhotoCure ASA Receives Payment for Development of Lumacan from Salix Pharmaceuticals Ltd


Wednesday, 2 Jan 2013 02:30am EST 

PhotoCure ASA announced that it has received a payment of USD 4.5 million from Salix Pharmaceuticals Ltd regarding development of Lumacan to date and the commitment to continue the development. Lumacan is a photodynamic colorectal diagnostic intended to significantly improve the detection of precancerous and cancerous lesions in the colon through fluorescence diagnosis. Photocure signed a strategic global agreement with Salix for the development and commercialization of Lumacan in October 2010. The collaboration with Salix is progressing well. Salix is currently developing an optimal oral formulation of Lumacan to be used in clinical studies. 

Company Quote

157.18
-3.62 -2.25%
4:00pm EDT